Related Experiment Video
Updated: Jun 27, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Low-dose hydrocortisone in pediatric septic shock: an exploratory study in a third world setting
Harsha T Valoor1, Sunit Singhi, M Jayashree
1Department of Pediatrics Advanced Pediatric Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Summary
Low-dose hydrocortisone showed a trend towards faster shock reversal and reduced inotrope needs in pediatric septic shock. Further studies are needed to confirm its efficacy in developing countries.
Area of Science:
- Pediatric critical care medicine
- Pediatric endocrinology
- Infectious diseases
Background:
- Septic shock in children is a life-threatening condition requiring prompt management.
- The role of corticosteroids in pediatric septic shock remains debated, particularly in resource-limited settings.
Purpose of the Study:
- To evaluate the efficacy of low-dose intravenous hydrocortisone in pediatric septic shock.
- To assess the impact on time to shock reversal and inotrope requirements.
Main Methods:
- An open-label, randomized pilot study was conducted in a tertiary care pediatric center.
- Thirty-eight children (2 months-12 years) with fluid-refractory septic shock received either hydrocortisone or normal saline for 7 days.
Main Results:
- Hydrocortisone treatment showed a trend towards earlier shock reversal (median 49.5 vs. 70 hours) and lower inotrope scores (median 20 vs. 50).
- These differences were not statistically significant (p=0.65 and p=0.15, respectively).
- Mortality rates were similar between the hydrocortisone and control groups.
Conclusions:
- The study suggests a potential benefit of low-dose hydrocortisone in pediatric septic shock, but results are inconclusive.
- Larger sample size studies are warranted to define its role, considering factors like malnutrition and delayed presentation in developing countries.
Related Concept Videos
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...